Autoimmune Pediatric CNS Disorders, CSF
Also known as: AIPEDC
Use
This test is used to evaluate subacute-onset encephalopathy, epilepsy, behavior changes, or movement disorders in individuals under 18 years old. Testing in both serum and CSF is recommended to maximize diagnostic yield. For serum testing, refer to Autoimmune Pediatric CNS Disorders, Serum (3006210).
Special Instructions
If NMDA CSF antibody IgG is positive, then titer will be performed. Additional charges apply for reflex testing, including for PCCA/ANNA antibodies if indeterminate results are obtained by IFA.
Limitations
A negative test result does not rule out a diagnosis of autoimmune encephalitis or limbic encephalitis. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings. This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
LOINC Codes
- 80220-7
- 14247-1
- 46718-3
- 82732-9
- 82984-6
- 90820-2
- 90830-1
- 42501-7
- 94283-9
- 103715-9
- 93500-7
Result Turnaround Time
3-10 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
3 mL
Minimum Volume
1.5 mL
Container
ARUP standard transport tubes
Collection Instructions
Transfer three 1 mL CSF aliquots to ARUP standard transport tubes. (Min: 0.5 mL/aliquot)
Patient Preparation
N/A
Causes for Rejection
Fluid other than CSF. Grossly hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 1 week |
| Frozen | 30 days |